Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders for Galectin Therapeutics Inc. (GALT), held on January 23, 2025. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The primary material event reported is the successful election of the board of directors and the ratification of the independent auditor. Key voting outcomes include:
- Election of Directors: All 11 nominees were elected. Votes withheld ranged from approximately 249,000 to 1,013,000 per director. Notably, there were 20,045,381 broker non-votes for each director.
- Ratification of Auditor: Stockholders ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the year ending December 31, 2024.
- Auditor Vote Breakdown: 38,723,588 votes For, 162,839 votes Against, and 408,919 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a standard disclosure of shareholder meeting results.
Investor Verification Checklist
- Verify the total number of shares outstanding to contextualize the 20 million+ broker non-votes.
- Confirm the tenure and qualifications of the newly elected directors, particularly those with higher withheld votes.
- Review the upcoming 2024 Annual Report (10-K) for the financial data not included in this 8-K.
- Check for any subsequent filings regarding the appointment of Cherry Bekaert LLP.